[Use of mepolizumab in hypereosinophilic syndromes: The position and proposals of the national reference center for hypereosinophilic syndromes]

J E Kahn; G Lefèvre; M Groh

doi:10.1016/j.revmed.2023.03.006

[Use of mepolizumab in hypereosinophilic syndromes: The position and proposals of the national reference center for hypereosinophilic syndromes]

Rev Med Interne. 2023 Apr;44(4):155-157. doi: 10.1016/j.revmed.2023.03.006.

[Article in French]

Authors

J E Kahn¹, G Lefèvre², M Groh³

Affiliations

¹ Centre de référence maladies rares des syndromes hyperéosinophiliques (CEREO), France; Service de médecine interne, hôpital Ambroise Paré, université Paris Saclay, 2, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France. Electronic address: jean-emmanuel.kahn@aphp.fr.
² Centre de référence maladies rares des syndromes hyperéosinophiliques (CEREO), France; Laboratoire d'immunologie, INFINITE - Institute for Translational Research in Inflammation, université de Lille, CHU de Lille, 59000 Lille, France.
³ Centre de référence maladies rares des syndromes hyperéosinophiliques (CEREO), France; Service de médecine interne, hôpital Foch, 92150 Suresnes, France.

PMID: 36997273
DOI: 10.1016/j.revmed.2023.03.006

No abstract available

Keywords: Anti-interleukin-5 antibodies; Anticorps anti-interleukine-5; Hypereosinophilic syndrome; Mepolizumab; Mépolizumab; Syndrome hyperéosinophilique.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Eosinophils
Humans
Hypereosinophilic Syndrome* / drug therapy

Substances

mepolizumab
Antibodies, Monoclonal, Humanized